Lin Ma
Shandong University
6 Papers
Lin Ma is an academic researcher from Shandong University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 2 publications.
Chat about Author
Papers
Primary Squamous Cell Carcinoma of the Liver is Rare but Hostile: Case Series and Comprehensive Review of the Literature
TL;DR: In this article, the authors reviewed three cases with primary SCC of the liver in a single center from January 2013 to October 2019 and found 25 patients with primary hepatic SCC in the Surveillance, Epidemiology and End Results (SEER) database from 1997 to 2016.
16
Clostridium butyricum alleviates dextran sulfate sodium-induced experimental colitis and promotes intestinal lymphatic vessel regeneration in mice
TL;DR: The findings suggest that C butyricum might alleviate IBD in DSS-induced IBD-model mice by promoting intestinal LV regeneration.
Impact of endogenous glucocorticoid on response to immune checkpoint blockade in patients with advanced cancer
Xinyue Han,Hongtao Liu,Qinfen Xie,Yaping Guan,Beibei Yin,Junjuan Xiao,Dongfeng Feng,Xuan Wang,Junwei Li,Jian Chen,Xiaolin Liu,Xingyu Li,Weiwei Nie,Lin Ma,Hairong Liu,Jing Liang,Yan Li,Baocheng Wang,Jun Hong Wang +18 more
TL;DR: In this paper , the effects of endogenous glucocorticoid (GC) levels on objective response rate (ORR), durable clinical benefit (DCB), progression-free survival (PFS), and overall survival (OS) were analyzed.
Machine learning to improve prognosis prediction of metastatic clear-cell renal cell carcinoma treated with cytoreductive nephrectomy and systemic therapy
Wenjie Yang,Lin Ma,Jie Dong,Mengchao Wei,Ruoyu Ji,Hualin Chen,Xiaoqiang Xue,Yingjie Li,Zhaoheng Jin,Weifeng Xu,Zhigang Ji +10 more
TL;DR: Wang et al. as mentioned in this paper used four ML models, i.e., a gradient boosting machine (GBM), support vector machine (SVM), random forest (RF), and logistic regression (LR), to predict the cancer-specific survival rate (CSS) at 1, 3, and 5 years.
7
SDK1-ALK Fusion in a Lung Adenocarcinoma Patient With Excellent Response to ALK Inhibitor Treatment: A Case Report
TL;DR: This is the first case of SDK1-ALK fusion with an excellent response to an ALK inhibitor, which will provide better understanding of ALK-TKI applications for NSCLC patients with ALK fusion in the future.